Impact of HER2 and PTEN Simultaneous Deregulation in Non-small Cell Lung Carcinoma: Correlation with Biological Behavior

Panagiotou, Ioannis; Georgiannos, Stavros N; Tsiambas, Evangelos; Karameris, Andreas; Konstantinou, Marios; Lazaris, Andreas C.; Kavantzas, Nikolaos; Vilaras, George; Patsouris, Efstratios

doi:10.7314/apjcp.2012.13.12.6311

Cited by 8 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, some authors failed to detect the relationship between the HER-2 status and NSCLC histogenesis [2]. The tumors were more often HER-2 + in cases with metastases to the lymph nodes than in tumors without metastases, which was in line with published data [9].…”

mentioning

confidence: 51%

See 1 more Smart Citation

Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer

et al. 2014

View full text Add to dashboard Cite

A total of 218 operation specimens from patients with nonsmall cell lung cancer were examined. The expression of HER-2 protein was studied by the immunohistochemical method, amplification of HER2 gene and centromere part of chromosome 17 (CEP17) - by the in situ chromogenic hybridization method. Moderate correlation (r=0.38, p<0.001) between the immunohistochemical status and HER2 gene amplification was detected. A relationship between TNM clinical morphological parameters and HER-2 protein content and chromosome 17 polysomia (for N parameter), HER-2 protein content, and HER2 gene amplification (for tumor histogenesis) was detected. The content of HER-2 protein and amplification of HER2 and CEP17 correlated with the clinical morphological parameters of patients with nonsmall cell lung cancer.

show abstract

mentioning

confidence: 51%

“…Analysis of the relevant publications showed no clear-cut correlations between the content of HER-2 protein and amplifi cation of its gene, on the one hand, and clinical morphological parameters of NSCLC, on the other [1][2][3][4][5]9,11,13].…”

mentioning

confidence: 99%

Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…HER2 has been reported to be overexpressed or amplified in a variety of human tumors (Nicholson et al, 2001;Rubin and Yarden, 2001;McAlpine et al, 2009;Ghaffari et al, 2011;Wang et al, 2011;Sardari et al, 2012;Duman et al, 2012;Panagiotou et al, 2012; RESEARCH ARTICLE Pazhoomand et al, 2013;Unal et al, 2013;Ziaian et al, 2014). The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Missaoui

Abdelkarim²,

Ayachi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Ovarian mucinous carcinoma has a poor prognosis in advanced stages and a poor response to conventional chemotherapy. An efficient treatment is not yet available. We heere investigated HER2 expression and the potential for trastuzumab therapy in ovarian mucinous tumors. Materials and Methods: Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tissue from 27 ovarian mucinous tumors including 14 carcinomas and 13 borderline tumors diagnosed in the Pathology Department, Farhet Hached Hospital, Sousse, between 1993 and 2013. The HercepTest (DAKO) was used for immunohistochemistry. Results: HER2 expression was observed in only one borderline tumor (7.7%) and in 14.3% of mucinous carcinomas of the ovary. Conclusions: Our results suggest that trastuzumab therapy would be an option for patients with mucinous carcinoma when the tumor has HER2 overexpression.

show abstract

“…37 More recently, chromogenic PTEN IHC was measured in NSCLC in the red-green-blue spectrum using Aperio ImageScope software and 6H2.1 antibody. 34,38 A similar approach was used for scoring PTEN expression in larynx carcinoma. 39 Furthermore, its intracellular localization, intensity, and frequency was assessed using 3D Histech Panoramic Viewer software and antibody clones 6H2.1, 138G6, and Ab6-28H6.…”

Section: Computerized Analysis Of Semiquantitative Intensity Marksmentioning

confidence: 99%

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort

Rulle

Tsourti

Casanova

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Impact of HER2 and PTEN Simultaneous Deregulation in Non-small Cell Lung Carcinoma: Correlation with Biological Behavior

Cited by 8 publications

References 34 publications

Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer

Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort

Contact Info

Product

Resources

About